Best Practices for the Management of Ocular Adverse Events Associated with ELAHERE (mirvetuximab soravtansine-gynx)

Published on: July 18, 2024

This resource is intended for eye doctors or oncologists looking to:

• Understand why patients on ELAHERE require eye exams, and when
• Learn about what ocular AEs may be experienced by patients on ELAHERE
• Review the proactive eye drops administration patients should take during treatment
• See resources available to help facilitate communication between eye doctors and oncologists

Watch video